chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 57.0
Sex: F
Vaccine: VARZOS
Symptoms: Abdominal discomfort, Anorexia, Dizziness, Injection site erythema, Injection site induration
Clinical narrative: Information has been received from a registered nurse concerning a 57 year old female patient with bipolar disorder, hypothyroidism, penicillin allergy and prednisone allergy and a history of post mastectomy for breast cancer, who on 23-FEB-2009 was vaccinated subcutaneously in the deltoid region with a 0.65 mL dose of ZOSTAVAX (Merck) (Lot #663895/0135Y). On 26-FEB-2009, the patient developed an injection site reaction. The area was raised, red, hard and warm. It was about the "size of a half dollar". The patient also experienced stomach upset, loss of appetite, nausea and felt lightheaded. The patient called the office. At the time of reporting, the patient had not recovered. Additional information has been requested.
Age: 57.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site reaction, Injection site swelling, Injection site warmth, Nausea
Clinical narrative: Information has been received from a registered nurse concerning a 57 year old female patient with bipolar disorder, hypothyroidism, penicillin allergy and prednisone allergy and a history of post mastectomy for breast cancer, who on 23-FEB-2009 was vaccinated subcutaneously in the deltoid region with a 0.65 mL dose of ZOSTAVAX (Merck) (Lot #663895/0135Y). On 26-FEB-2009, the patient developed an injection site reaction. The area was raised, red, hard and warm. It was about the "size of a half dollar". The patient also experienced stomach upset, loss of appetite, nausea and felt lightheaded. The patient called the office. At the time of reporting, the patient had not recovered. Additional information has been requested.
Age: 79.0
Sex: F
Vaccine: VARZOS
Symptoms: Muscle tightness, Musculoskeletal stiffness
Clinical narrative: Information has been received from a pharmacist concerning a 79 year old female patient, who on 20-FEB-2009, was vaccinated with ZOSTAVAX (Merck), 0.65ml, subcutaneously in arm. In the week of 23-FEB-2009, the patient experienced stiffness in her neck/tight muscles in her neck a few days after receiving ZOSTAVAX (Merck). The patient called the pharmacy to seek for medical attention. At the time of the report, the patient had not recovered. Additional information has been requested.
Age: 66.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a physician concerning a 66 year old female who in 2008, "a few months ago", was vaccinated subcutaneously with a single 0.65 ml dose of ZOSTAVAX (Merck). The physician reported that the patient developed shingles after she was given ZOSTAVAX (Merck). At the time of the report, the outcome was unknown. Unspecified medical attention was sought. Additional information has been requested.
Age: 85.0
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster, Pain, Rash
Clinical narrative: Information has been received from a registered nurse concerning an 87 year old male who was vaccinated with a dose of ZOSTAVAX (Merck) on an unspecified date. Subsequently the patient developed a light case of shingles after receiving ZOSTAVAX (Merck). He recovered on an unspecified date. The patient sought unspecified medical attention. Follow up information was received from registered nurse who reported the 85 year old (previously reported as 87 year old) male patient with congestive heart failure (CHF) and atrial fibrillation (A-fib) was subcutaneously vaccinated with the first 0.6 ml dose of ZOSTAVAX (Merck) (lot # 656608/0032U) on 01-MAR-2007. There was no illness at time vaccination. He developed mild rash on the left side of face and forehead but complained of significant pain on 18-DEC-2008. The rash did not occur at the site of injection or elsewhere within 42 days of the vaccination. By 05-JAN-2009 the patient denied pain. He was seen by and advanced registered nurse practitioner (ARNP) and treated with antiviral medication. The patient was seen on another clinic so limited information. He recovered on approximate 05-JAN-2009. Additional information is expected.
Age: 76.0
Sex: F
Vaccine: VARZOS
Symptoms: Cough, Injection site induration, Injection site mass, Injection site warmth, Sneezing
Clinical narrative: Information has been received from an office manager concerning a 76 year old female who on 10-FEB-2009 was subcutaneously vaccinated with a dose of ZOSTAVAX (Merck). On 10-FEB-2009 the patient developed a hard and hot lump the size of silver dollar at the injection site. The next day she started sneezing and coughing. She recovered one week after receiving ZOSTAVAX (Merck). The patient sought unspecified medical attention. Follow up information was received from a health professional concerning the patient with no illness at time of vaccination who was subcutaneously vaccination with the first dose of ZOSTAVAX (Merck) (lot #662855/1623X) at 15:30 on 02-FEB-2009 (previously reported as 10-FEB-2009) in the left arm. On 02-FEB-2009 (previously reported as 10-FEB-2009) the patient had a red spot on arm with size of a silver dollar. There was no pain. Then about 3 days after injection, on 05-FEB-2009 approximately, the patient got an upper respiratory infection. Additional information has been requested.
Age: 76.0
Sex: F
Vaccine: VARZOS
Symptoms: Upper respiratory tract infection
Clinical narrative: Information has been received from an office manager concerning a 76 year old female who on 10-FEB-2009 was subcutaneously vaccinated with a dose of ZOSTAVAX (Merck). On 10-FEB-2009 the patient developed a hard and hot lump the size of silver dollar at the injection site. The next day she started sneezing and coughing. She recovered one week after receiving ZOSTAVAX (Merck). The patient sought unspecified medical attention. Follow up information was received from a health professional concerning the patient with no illness at time of vaccination who was subcutaneously vaccination with the first dose of ZOSTAVAX (Merck) (lot #662855/1623X) at 15:30 on 02-FEB-2009 (previously reported as 10-FEB-2009) in the left arm. On 02-FEB-2009 (previously reported as 10-FEB-2009) the patient had a red spot on arm with size of a silver dollar. There was no pain. Then about 3 days after injection, on 05-FEB-2009 approximately, the patient got an upper respiratory infection. Additional information has been requested.
Age: 63.0
Sex: F
Vaccine: VARZOS
Symptoms: Oral herpes
Clinical narrative: Information has been received from a medical assistant concerning a 63 year old female patient with allergy to tetanus shot and a history of bowel irregularities, spastic colon and seasonal allergy who in January 2009, was vaccinated with one dose of ZOSTAVAX (Merck). Concomitant therapy included SYNTHROID and BONIVA. In February 2009, the patient developed a big cold sore. The patient had never had a cold sore and believed it was from ZOSTAVAX (Merck). The patient had been seen physician for medical attention. On an unspecified date, the patient recovered from the big cold sore. Additional information has been requested.
Age: 61.0
Sex: M
Vaccine: VARZOS
Symptoms: Body temperature increased, Influenza like illness, Pyrexia
Clinical narrative: Information has been received from a physician concerning himself over 60 year old who was vaccinated with a dose of ZOSTAVAX (Merck) (specific date not given). Subsequently the patient experienced flu like symptoms and had a fever of 102 at that weekend. He felt better a couple days later on unspecified therapies and recovered a couple days after receiving ZOSTAVAX (Merck). He did not seek medical attention. Follow up information was received from the physician who reported himself did not have illness at time of vaccination and medical history or drug allergy. There was no relevant diagnostic laboratory test. He was vaccinated with a dose of ZOSTAVAX (Merck) on 12-FEB-2009. At 12:00 on 15-FEB-2009 he experienced fever for 102 and chills for 48 hours. Additional information is not expected.
Age: 62.0
Sex: M
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site swelling, Injection site warmth
Clinical narrative: Information has been received from a certified medical assistant concerning a male with hypertension and sleep apnea and no allergies reported who was vaccinated SC in the upper arm with a dose of ZOSTAVAX (Merck) (Lot number 663894/0129Y) (dose not reported). Subsequently the patient experienced injection site redness, injection site warmth and injection site swelling on an unknown date. The patient sought medical attention by calling to the office. Additional information has been requested. Follow up information has been received from a physician concerning a 62 year old male with hypertension, sleep apnoea and asthma and no known drug allergies and no illness at the time of vaccination, who on 23-FEB-2009 was vaccinated SQ in left deltoid with first dose of ZOSTAVAX (Merck) (dose not reported) (lot number 663894/0129Y). Concomitant therapy included ADVAIR, albuterol, PROTONA 40mg QID, enalapril maleate (manufacturer unknown) 10mg QID, LIPITOR 10mg QID and AGGRENOX 25-200mg BID. The physician reported that on 24-FEB-2009 the patient had redness, warmth and swelling at injection site. The patient went to the office on 28-FEB-2009 and was evaluated no medical information available. The patient went for a follow up on 18-MAR-2009. The patient reported that still had small red spot at the injection site, but no other symptoms or problems. Subsequently, the patient recovered from injection site warmth and injection site swelling. The patient's injection site redness persisted. Additional information is not expected.
Age: 71.0
Sex: F
Vaccine: VARZOS
Symptoms: Fear of needles, Injection site erythema, Injection site mass, Injection site pruritus
Clinical narrative: Information has been received from a physician concerning a 71 year old female who on 24-FEB-2009, was vaccinated with a dose of ZOSTAVAX (Merck) (lot number, dose and route not reported). On 25-FEB-2009, the patient experienced itching around the injection site. The physician reported that the patient put ice on the site and she had recovered on an unknown date. The patient sought medical attention by calling the physician. Additional information has been requested. Follow up Information has been received from a physician concerning a 71 year old female with hypertension, gastrooesophageal reflux disease, fibrocystic breast and allergy to codeine, allergy to NAPROSYN, allergy to NSAIDS, allergy to PREVACID, allergy to CLARINEX and allergy to EVISTA, with no illness at the time of vaccination, who on 24-FEB-2009 was vaccinated with first dose of ZOSTAVAX (Merck) (dose and route not reported) (lot number 663174/1552X) after 1:00 PM. The physician reported on the day of vaccination, the patient tensed up because she was afraid of needles. The physician also reported that the patient did not remove the bandage until the following day (25-FEB-2009) during lunch as her arm of injection site started itching. Then she realized that bandage was still there and she noticed a "50 cent coin" size red bump (an array of small red bumps forming a "50 cent coin"). The was a raised bump. Patient applied an ice pack to stop the itching; then she put BENADRYL cream on the area on 25-FEB-2009. Patient called the physician to inform her. No vesicles, bumps and redness went away after one week. Recovery date reported as 04-MAR-2009. No further information is available.
Sex: F
Vaccine: VARZOS
Symptoms: Injection site rash, Injection site vesicles
Clinical narrative: Information has been received from a registered pharmacist concerning a female patient "over 60 years of age", who was vaccinated with a dose of ZOSTAVAX (Merck) (lot# not reported) 0.65ml subcutaneously. One day after the vaccination, the patient developed a localized zoster-like rash at the injection site. Patient sought medical attention via a telephone call. No lab diagnostic studies were performed. The rash lasted 2 days and then the patient recovered. No further information is available.
Age: 73.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a Nurse Practitioner (N.P.) concerning a 73 year old female patient who "last year" was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck). It was reported that the patient experienced a breakthrough case of shingles after receiving ZOSTAVAX (Merck) about a year ago. It was reported that the patient had not recovered at the time of the report. The patient sought unspecified medical attention. Follow up information was received from a Nurse Practitioner (N.P.) who reported that on 23-FEB-2009 a 73 year old female patient at 08:43 developed a severe case of shingles on her left chest wall 10 months after receiving ZOSTAVAX (Merck). There was no illness at time of vaccination. It was reported that the patient recovered on 05-MAR-2009. Additional information is not expected.
Sex: M
Vaccine: VARZOS
Symptoms: Fall
Clinical narrative: Information has been received from a registered pharmacist concerning a male patient who on 25-FEB-2009 was vaccinated with a dose of ZOSTAVAX (Merck) at another pharmacy. The pharmacist reported that in the morning of 26-FEB-2009, 27-FEB-2009 and 28-FEB-2009, the patient fell upon arising. The patient did not sustain injury. The patient sought medical attention by calling the pharmacist. Additional information has been requested.
Age: 74.0
Sex: F
Vaccine: VARZOS
Symptoms: Urticaria
Clinical narrative: Information has been received from a physician concerning a 75 year old female who in May 2008, was vaccinated with ZOSTAVAX (Merck) (lot no. route and site not reported). The physician reported that the patient had experienced persistent hives since vaccination. The patient was seeing by the physician. At the time of reporting the patient had not recovered. Additional information has been requested.
Age: 64.0
Sex: F
Vaccine: VARZOS
Symptoms: Asthenia, Blood cholesterol increased, Blood urea increased, Carbon dioxide abnormal, Chest X-ray normal
Clinical narrative: Information has been received from a nurse practitioner concerning an "over 60" year old female patient with hypertension and cholesterol high, who on 09-JAN-2009 was vaccinated with a 0.65 mL dose of ZOSTAVAX (Merck) (Lot # 663177/1413X). On 23-JAN-2009, the patient developed fever blister on lips after getting ZOSTAVAX (Merck). The patient sought unspecified medical attention. On an unspecified date, the patient had recovered. Follow up information has been received from a registered nurse concerning a 65 year old female patient with iodine, hydrochlorothiazide (WAES # 0904USA04510) and sulfa allergy, depression, hypertension and hyperlipidemia, who on 09-JAN-2009 at afternoon was vaccinated with the first dose ZOSTAVAX (Merck) (Lot # 663177/1413X) 0.65 mL on the left triceps. Concomitant therapy included atenolol, PAXIL and LIPITOR. On 09-JAN-2009, laboratory tests performed showed the following results: white blood cell count low 3.8 K/uL (4.0-11.0); questionable viral illness. On 05-FEB-2009 at 09:44 (also reported on 23-JAN-2009), the patient experienced fever blister and was treated with VALTREX, 1 gm BID for 5 days. On 17-FEB-2009, chest X-ray was performed which was normal. On 19-FEB-2009, the patient experienced cough and no energy, she was seen and evaluated, the patient complained of being ill for 4 weeks (felt like when she had mono). The oral fever blister had resolved. Fatigue persisted. On 25-FEB-2009, was reported that on 20-FEB-2009 glucose, kidney, liver test, complete blood count, normal limits. Viral titers showed chronic mono, like viral infection. Laboratory results showed the following results: blood eosinophilic leukocyte count 8% (0-7), serum Epstein-Barr virus nuclear antigen immunoglobulin G antibody test in range 9.1 U/mL, serum Epstein-Barr virus early antigen immunoglobulin G antibody test high 10.2 U/mL, serum Epstein-Barr viral capsid antigen immunoglobulin M antibody test in range less than 10.0, the interpretive table showed a chronic infection. On 05-APR-2009, the patient recovered from the adverse events. No further information is available.
Age: 64.0
Sex: F
Vaccine: VARZOS
Symptoms: Cough, Eosinophil count increased, Epstein-Barr virus antibody positive, Epstein-Barr virus antigen positive, Fatigue
Clinical narrative: Information has been received from a nurse practitioner concerning an "over 60" year old female patient with hypertension and cholesterol high, who on 09-JAN-2009 was vaccinated with a 0.65 mL dose of ZOSTAVAX (Merck) (Lot # 663177/1413X). On 23-JAN-2009, the patient developed fever blister on lips after getting ZOSTAVAX (Merck). The patient sought unspecified medical attention. On an unspecified date, the patient had recovered. Follow up information has been received from a registered nurse concerning a 65 year old female patient with iodine, hydrochlorothiazide (WAES # 0904USA04510) and sulfa allergy, depression, hypertension and hyperlipidemia, who on 09-JAN-2009 at afternoon was vaccinated with the first dose ZOSTAVAX (Merck) (Lot # 663177/1413X) 0.65 mL on the left triceps. Concomitant therapy included atenolol, PAXIL and LIPITOR. On 09-JAN-2009, laboratory tests performed showed the following results: white blood cell count low 3.8 K/uL (4.0-11.0); questionable viral illness. On 05-FEB-2009 at 09:44 (also reported on 23-JAN-2009), the patient experienced fever blister and was treated with VALTREX, 1 gm BID for 5 days. On 17-FEB-2009, chest X-ray was performed which was normal. On 19-FEB-2009, the patient experienced cough and no energy, she was seen and evaluated, the patient complained of being ill for 4 weeks (felt like when she had mono). The oral fever blister had resolved. Fatigue persisted. On 25-FEB-2009, was reported that on 20-FEB-2009 glucose, kidney, liver test, complete blood count, normal limits. Viral titers showed chronic mono, like viral infection. Laboratory results showed the following results: blood eosinophilic leukocyte count 8% (0-7), serum Epstein-Barr virus nuclear antigen immunoglobulin G antibody test in range 9.1 U/mL, serum Epstein-Barr virus early antigen immunoglobulin G antibody test high 10.2 U/mL, serum Epstein-Barr viral capsid antigen immunoglobulin M antibody test in range less than 10.0, the interpretive table showed a chronic infection. On 05-APR-2009, the patient recovered from the adverse events. No further information is available.
Age: 64.0
Sex: F
Vaccine: VARZOS
Symptoms: Low density lipoprotein increased, Malaise, Oral herpes, Viral infection, White blood cell count decreased
Clinical narrative: Information has been received from a nurse practitioner concerning an "over 60" year old female patient with hypertension and cholesterol high, who on 09-JAN-2009 was vaccinated with a 0.65 mL dose of ZOSTAVAX (Merck) (Lot # 663177/1413X). On 23-JAN-2009, the patient developed fever blister on lips after getting ZOSTAVAX (Merck). The patient sought unspecified medical attention. On an unspecified date, the patient had recovered. Follow up information has been received from a registered nurse concerning a 65 year old female patient with iodine, hydrochlorothiazide (WAES # 0904USA04510) and sulfa allergy, depression, hypertension and hyperlipidemia, who on 09-JAN-2009 at afternoon was vaccinated with the first dose ZOSTAVAX (Merck) (Lot # 663177/1413X) 0.65 mL on the left triceps. Concomitant therapy included atenolol, PAXIL and LIPITOR. On 09-JAN-2009, laboratory tests performed showed the following results: white blood cell count low 3.8 K/uL (4.0-11.0); questionable viral illness. On 05-FEB-2009 at 09:44 (also reported on 23-JAN-2009), the patient experienced fever blister and was treated with VALTREX, 1 gm BID for 5 days. On 17-FEB-2009, chest X-ray was performed which was normal. On 19-FEB-2009, the patient experienced cough and no energy, she was seen and evaluated, the patient complained of being ill for 4 weeks (felt like when she had mono). The oral fever blister had resolved. Fatigue persisted. On 25-FEB-2009, was reported that on 20-FEB-2009 glucose, kidney, liver test, complete blood count, normal limits. Viral titers showed chronic mono, like viral infection. Laboratory results showed the following results: blood eosinophilic leukocyte count 8% (0-7), serum Epstein-Barr virus nuclear antigen immunoglobulin G antibody test in range 9.1 U/mL, serum Epstein-Barr virus early antigen immunoglobulin G antibody test high 10.2 U/mL, serum Epstein-Barr viral capsid antigen immunoglobulin M antibody test in range less than 10.0, the interpretive table showed a chronic infection. On 05-APR-2009, the patient recovered from the adverse events. No further information is available.
Age: 63.0
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster, Rash
Clinical narrative: Information has been received from a Licensed Practical Nurse concerning a 64 year old male patient who on 16-JAN-2009 was vaccinated with a dose of ZOSTAVAX (Merck) (Lot # 663672/1709X). It was reported that on 21-JAN-2009 the patient presented in office with rash under left arm. It was diagnosed to be shingles. A ZOSTRIX and NEURONTIN were prescribed. Additional information has been requested.
Age: 67.0
Sex: M
Vaccine: VARZOS
Symptoms: Pain, Rash vesicular, Virus culture negative
Clinical narrative: Information has been received from a physician concerning a 67 year old male with a hypertension and hypothyroidism and a history of multiple non-melanoma skin cancers, no known drugs allergies, who on 27-FEB-2009 was vaccinated with a dose of ZOSTAVAX (Merck) subcutaneously into the left arm. Concomitant therapy included SYNTHROID, verapamil, hydrochlorothiazide (manufacturer unknown), allopurinol, losartan potassium (MSD), aspirin and multi-vitamins (unspecified). On 02-MAR-2009 the patient developed dermatomal zoster like lesions after administration of ZOSTAVAX (Merck). The patient had approximately 15 lesions at the right T5 dermatome. Patient was experiencing pain. On 03-MAR-2009 a viral culture was performed. The patient sought medical attention through an office visit. At the time of this report the patient had not recovered. Follow up information received on 22-APR-2009 from the physician stated that a patient, with a zoster like reaction at the time of vaccination and a negative culture recovered 1 week later. No further information is available.
Age: 66.0
Sex: F
Vaccine: VARZOS
Symptoms: Blister, Erythema, Fatigue, Herpes zoster, Pain
Clinical narrative: Information has been received from a registered pharmacist concerning a 66 year old female with allergies to Ibuprofen and CEFTIN who on 26-FEB-2009 was subcutaneously vaccinated with the first 0.65 ml dose of ZOSTAVAX (Merck) (lot #663672/1709X). On 28-FEB-2009 the patient developed shingles rash on her lower abdomen and back. It was noted that the patient was placed on antiviral therapy to treat the shingles. She did not recover at the time of reporting. The patient was seen by the physician for medical attention. Follow up information was received from the pharmacist and physician who reported that the patient was seen by the physician because she had a reaction since the shingles vaccine was given at the pharmacy on 26-Feb-2009. On 28-Feb-2009 she started having a little bit of burning pain on the right lower aspect of her abdomen. As of report, she had a rash with blistering that came out on 02-MAR-2009 and it seemed to be extending around towards the back. Otherwise no fevers, chills or sweats. She felt kind of tired, though no specific complains. Vital signs were listed that the patient's weight was 183 and blood pressure was 128/72. Exam revealed on the L1 dermatome, or in the vicinity on her right side, a patch of erythema, old blisters. On the anterior aspect of the abdomen, right lower quadrant, extension around with some patchy similar lesions toward the back, not crossing the midline. No sign of superinfection. Assessment was that of shingles, zoster outbreak following the injection of the vaccine. In central, the patient noted she might have had chickenpox as a child, although all 3 of her children were exposed it was presumed she was exposed as well. The patient was given VALTREX 1000 mg, tid, for 7 day. She was recommended keeping the area clean and watching for signs of infection. Cortisone for itch, if necessary. She was instructed to contact the physician if her symptoms did not improve or worsened. The outcome was not reported. Additional information has been requested.
Age: 66.0
Sex: F
Vaccine: VARZOS
Symptoms: Rash, Skin burning sensation
Clinical narrative: Information has been received from a registered pharmacist concerning a 66 year old female with allergies to Ibuprofen and CEFTIN who on 26-FEB-2009 was subcutaneously vaccinated with the first 0.65 ml dose of ZOSTAVAX (Merck) (lot #663672/1709X). On 28-FEB-2009 the patient developed shingles rash on her lower abdomen and back. It was noted that the patient was placed on antiviral therapy to treat the shingles. She did not recover at the time of reporting. The patient was seen by the physician for medical attention. Follow up information was received from the pharmacist and physician who reported that the patient was seen by the physician because she had a reaction since the shingles vaccine was given at the pharmacy on 26-Feb-2009. On 28-Feb-2009 she started having a little bit of burning pain on the right lower aspect of her abdomen. As of report, she had a rash with blistering that came out on 02-MAR-2009 and it seemed to be extending around towards the back. Otherwise no fevers, chills or sweats. She felt kind of tired, though no specific complains. Vital signs were listed that the patient's weight was 183 and blood pressure was 128/72. Exam revealed on the L1 dermatome, or in the vicinity on her right side, a patch of erythema, old blisters. On the anterior aspect of the abdomen, right lower quadrant, extension around with some patchy similar lesions toward the back, not crossing the midline. No sign of superinfection. Assessment was that of shingles, zoster outbreak following the injection of the vaccine. In central, the patient noted she might have had chickenpox as a child, although all 3 of her children were exposed it was presumed she was exposed as well. The patient was given VALTREX 1000 mg, tid, for 7 day. She was recommended keeping the area clean and watching for signs of infection. Cortisone for itch, if necessary. She was instructed to contact the physician if her symptoms did not improve or worsened. The outcome was not reported. Additional information has been requested.
Age: 72.0
Sex: F
Vaccine: VARZOS
Symptoms: Pruritus generalised
Clinical narrative: Information has been received from a registered pharmacist concerning a 72 year old female patient with a history of hypertension who on 25-JAN-2009 was vaccinated with ZOSTAVAX (Merck) SQ at the pharmacy. Concomitant therapy included Lisinopril (manufacturer unspecified), Hydrochlorothiazide (manufacturer unspecified), and atenolol (manufacturer unspecified). On 01-FEB-2009 the patient experienced intermittent episodes of widespread itchiness. The itchiness "all over her body" was not associated with a rash and responds to topical hydrocortisone cream. The patient went to the pharmacy for medical attention. The patient's intermittent episodes of widespread itchiness persisted. Follow-up information has been received from the registered pharmacist that on 12:00 PM 25-JAN-2009 the female patient with depression, high blood pressure and no allergies was vaccinated with her first dose of ZOSTAVAX (Merck) (lot # 662855/1623X) SQ at the pharmacy. On PM 25-JAN-2009 the patient called back to the pharmacy complaining about persistent widespread itchiness after receiving the vaccine. The registered pharmacist called the patient "today" and the patient said that itchiness was gone. The patient had never gone to the Emergency Room, hospital or the doctor's office to seek help for the itchiness. No further information is available.
Age: 60.0
Sex: F
Vaccine: PPV, VARZOS
Symptoms: Activities of daily living impaired, Malaise, Oedema peripheral, Vomiting, Wrong technique in drug usage process
Clinical narrative: Information has been received from a pharmacist concerning an approximately 60 year old female who on 25-Feb-2009 was vaccinated with ZOSTAVAX (Merck) that was reconstituted with PNEUMOVAX vaccine on 25-Feb-2009. The last couple of days in approximately February 2009, the patient developed swelling on her arm (unspecified arm), and had been in bed for a couple of days from not feeling well after vaccination. The pharmacist contacted the physician. At the time of this report, the patient's swelling of her arm, not feeling well and vomiting persisted. This is one of several reports received from the same source. Additional information has been requested.
Age: 71.0
Sex: F
Vaccine: VARZOS
Symptoms: Lip swelling, Oropharyngeal blistering, Stomatitis
Clinical narrative: Information has been received from a pharmacist concerning a 71 year old female with allergic reaction to ZITHROMAX who on 02-MAR-2009 was vaccinated with a single dose left upper arm of ZOSTAVAX (Merck) SQ, lot number 663673/1710X. On 03-MAR-2009 the patient developed lip swelling and blisters inside her mouth. The patient self-treated with BENADRYL. The patient contacted the pharmacist that the same day was coming to the pharmacist on 04-MAR-2009, the patient had a small raised area, about the size of the head of a pin on the inside of her lower lip and redness across the entire inside of the lower lip. The patient's lip swelling and blisters inside her mouth and redness across of the entire of her lower lip persisted. Additional information has been requested.
Age: 60.0
Sex: M
Vaccine: VARZOS
Symptoms: Pityriasis rosea, Rash
Clinical narrative: Information has been received from a physician concerning a 60 year old female banker with a history of type II diabetes mellitus and no acute illness at time of vaccination,who on 21-Jan-2009 at 12:00 was vaccinated with a first dose of ZOSTAVAX (Merck) (lot# 663572/1709X), subcutaneously into the left arm. On 25-Feb-2009 the patient experienced rash most consistent with pityriasis rosea. No further information is available.
Sex: U
Vaccine: VARZOS
Symptoms: Rash vesicular
Clinical narrative: Information has been received from a licensed practical nurse concerning a patient with no known drug reaction/allergies; who on an unspecified date, was vaccinated with ZOSTAVAX (Merck). The reporter stated that the patient had a shingles like rash 3 days after the vaccine was given. At the time of the report, the patient had not recovered. The patient sought medical attention and contacted the nurse's office. No further information is available.
Age: 86.0
Sex: M
Vaccine: VARZOS
Symptoms: Burning sensation, Pain, Paraesthesia
Clinical narrative: Information has been received from a consumer concerning her 86 year old husband with diabetes and hypertension and a history of brain tumor. No known drug allergies/drug reactions, who on 14-NOV-2008 was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). It was reported that the patient had shingles four months prior to the vaccination. It was reported that the patient was still having pain, tingling and burning where the shingles were following vaccination. A laboratory work was performed (results not provided). It was reported that the patient had not recovered at the time of the report. The patient sought unspecified medical attention. No further information is available.
Age: 42.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site rash, Pyrexia
Clinical narrative: Information has been received from a pharmacist concerning a 42 year old female patient with chronic shoulder pain, asthma and unspecified allergies and no illness at the time of vaccination who on 29-DEC-2008 was vaccinated with ZOSTAVAX (Merck) (lot # 662857/1560X) SQ. Concomitant therapy included VICODIN. On 30-DEC-2008 the patient developed a red rash at the injection site of the right arm and a fever. The patient had sought unspecified medical attention. The symptoms resolved on 01-JAN-2009 without treatment. This is one of several reports from the same source. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Rash
Clinical narrative: Information has been received from a physician concerning a female who was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) on an unspecified date. Subsequently the patient developed rash on forehead after getting ZOSTAVAX (Merck). At the time of reporting she was recovering. The patient sought unspecified medical attention. Additional information has been requested.
Age: 67.0
Sex: F
Vaccine: VARZOS
Symptoms: Musculoskeletal pain, Myalgia, Pain in extremity
Clinical narrative: Information has been received from a Doctor of pharmacy concerning a 67 year old female patient with no drug reactions/allergies and hypercholesterolemia who on 18-FEB-2009 was vaccinated with single dose of ZOSTAVAX (Merck) (lot # 663177/1413X) SQ at the pharmacy. Concomitant therapy included statin (unspecified). Since 19-FEB-2009 or 20-FEB-2009 the patient had developed intermittent muscle pain of the left arm and shoulder. The patient had contacted pharmacist for medical attention. No lab diagnostics were performed. The patient's intermittent muscle pain of the left arm and shoulder persisted. This is one of several reports from the same source. Additional information has been requested.
Age: 67.0
Sex: F
Vaccine: VARZOS
Symptoms: Chills, Injection site erythema, Injection site reaction, Injection site swelling, Injection site warmth
Clinical narrative: Information has been received from a pharmacist concerning a 67 year old female with no drug allergies who on 03-MAR-2009 was subcutaneously vaccinated with a dose of ZOSTAVAX (Merck) (lot #663673/1710X). On 03-MAR-2009 the patient developed an injection site reaction after vaccination with ZOSTAVAX (Merck). The reaction was manifest as a red area of about 2 inches by 2 inches. The area was raised, hot to touch and the patient also had chills. As of 06-MAR-2009, the patient was recovering. The patient called pharmacist for medical attention. Additional information has been requested.
Age: 65.0
Sex: M
Vaccine: VARZOS
Symptoms: Immediate post-injection reaction, Injection site erythema, Injection site haematoma, Injection site induration, Injection site pruritus
Clinical narrative: Information has been received from a pharmacist concerning a 65 year old male patient who on 03-MAR-2009 was vaccinated with ZOSTAVAX (Merck) (lot # 663894/0129Y) SQ. The patient had been taking monoclonal antibody for a study but discontinued on 29-DEC-2008. On 05-MAR-2009 or 06-MAR-2009, 2 to 3 days after administration of ZOSTAVAX (Merck), the patient experienced injection site reactions. The patient experienced erythema, swelling, induration, pruritus, bruising at the injection site and swelling of his entire arm. The pharmacist also reported that patient reported redness and itchiness immediately after administration. The patient had sought unspecified medical attention via telephone. At the time of reporting the patient's adverse events persisted. This is one of several reports from the same source. Additional information has been requested.
Age: 65.0
Sex: M
Vaccine: VARZOS
Symptoms: Injection site reaction, Injection site swelling, Oedema peripheral
Clinical narrative: Information has been received from a pharmacist concerning a 65 year old male patient who on 03-MAR-2009 was vaccinated with ZOSTAVAX (Merck) (lot # 663894/0129Y) SQ. The patient had been taking monoclonal antibody for a study but discontinued on 29-DEC-2008. On 05-MAR-2009 or 06-MAR-2009, 2 to 3 days after administration of ZOSTAVAX (Merck), the patient experienced injection site reactions. The patient experienced erythema, swelling, induration, pruritus, bruising at the injection site and swelling of his entire arm. The pharmacist also reported that patient reported redness and itchiness immediately after administration. The patient had sought unspecified medical attention via telephone. At the time of reporting the patient's adverse events persisted. This is one of several reports from the same source. Additional information has been requested.
Age: 71.0
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a physician concerning a 71 year old male patient who on 27-FEB-2009 was vaccinated with one dose of ZOSTAVAX (Merck) (lot # not available).  "Shortly after receiving ZOSTAVAX (Merck)" on 05-MAR-2009 the patient developed an active case of shingles.  The patient had sought unspecified medical attention.  The outcome of the patient's shingles was not reported.  Additional information has been requested.
Age: 73.0
Sex: F
Vaccine: VARZOS
Symptoms: Rash
Clinical narrative: Information has been received from a pharmacist concerning a 73 year old female with penicillin allergy, sulfa allergy, allergy codeine, fish allergy and mercury sensitivity in December 2008, was vaccinated with ZOSTAVAX (Merck).  Concomitant therapy included PLAQUENIL, BENICAR, SYNTHROID, estrogens, PREMARIN, LASIX.  The pharmacist reported the patient developed a rash under both her armpits and elbows after administration of the vaccine.  Additional information was not provided.  Additional information is not expected.
Age: 71.0
Sex: F
Vaccine: VARZOS
Symptoms: Injected limb mobility decreased, Musculoskeletal pain, Pain, Pain in extremity
Clinical narrative: Information has been received from a 71 year old female who on 05 -JAN-2009 or 06 -JAN-2009 was vaccinated with a dose of ZOSTAVAX (Merck) at a pharmacy. There was no concomitant medication. On approximately 05-JAN-2009 or 06 -JAN-2009 "right after getting the vaccine" she was still experiencing pain in her arm, it seemed like she could not get any movement out of her arm, it was achy and she had trouble lifting it. The pain seemed to be going to her shoulder. The patient's pain in her arm and any movement out of her arm persisted. Unspecified medical attention was sought. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Erythema, Fatigue, Urticaria
Clinical narrative: Information has been received from a registered nurse with no known medical history and drugs allergies, who on 03-May-2009 was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck), subcutaneously. Concomitant therapy included ACTIVELLA, Hydrochlorothiazide (manufacturer unknown), Lisinopril (manufacturer unknown) and PROTONIX. On 03-Mar-2009 the patient developed a big, red welt after the ZOSTAVAX (Merck). It was also stated that it had been getting better with each day. No laboratories studies performed. The patient did not seek medical attention. On 09-Mar-2009 the patient had recovered from the big, red welt. Follow up information received on 23-Mar-2009 from the registered nurse stated that she also felt fatigues during the first week after receiving the dose of ZOSTAVAX (Merck). Additional information has been requested.
Age: 70.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a physician concerning a 70 year old female who was subcutaneously vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) 2 years ago. Subsequently the patient developed shingles that was diagnosed by her dermatologist after having gotten ZOSTAVAX (Merck) on an unspecified date. The outcome was not reported. The patient sought unspecified medical attention. Additional information has been requested.
Age: 62.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site pruritus, Injection site swelling, Urticaria
Clinical narrative: Information has been received from a consumer concerning a 62 year old female who on 03-MAR-2009 was vaccinated with a dose of ZOSTAVAX (Merck). In the evening of 04-MAR-2009 the patient ate shrimp and broke out into hives. Also the injection site was itchy and swollen. No other information was provided. Additional information has been requested.
Age: 79.0
Sex: F
Vaccine: VARZOS
Symptoms: Immediate post-injection reaction, Injection site erythema, Injection site haematoma, Injection site induration, Injection site pain
Clinical narrative: Information has been received from a pharmacist concerning a 79 year old female patient with allergic reaction to neomycin who on 03-MAR-2009 was vaccinated with ZOSTAVAX (Merck) (lot # 663894/0129Y) SQ. On 05-MAR-2009 or 06-MAR-2009, 2 to 3 days after administration of ZOSTAVAX (Merck), the patient experienced injection site reactions. The patient developed a knot, swelling, soreness, erythema, pruritus, bruising and redness by the site of injection. The pharmacist stated that most patients reported the redness and itchiness immediately after administration. The patient had sought unspecified medical attention via telephone. At the time of reporting the patient's adverse events persisted. This is one of several reports from the same source. Additional information has been requested.
Age: 79.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site pruritus, Injection site swelling
Clinical narrative: Information has been received from a pharmacist concerning a 79 year old female patient with allergic reaction to neomycin who on 03-MAR-2009 was vaccinated with ZOSTAVAX (Merck) (lot # 663894/0129Y) SQ. On 05-MAR-2009 or 06-MAR-2009, 2 to 3 days after administration of ZOSTAVAX (Merck), the patient experienced injection site reactions. The patient developed a knot, swelling, soreness, erythema, pruritus, bruising and redness by the site of injection. The pharmacist stated that most patients reported the redness and itchiness immediately after administration. The patient had sought unspecified medical attention via telephone. At the time of reporting the patient's adverse events persisted. This is one of several reports from the same source. Additional information has been requested.
Age: 74.0
Sex: M
Vaccine: VARZOS
Symptoms: Immediate post-injection reaction, Injection site erythema, Injection site haematoma, Injection site induration, Injection site pruritus
Clinical narrative: Information has been received from a pharmacist concerning a 74 year old male patient who on 03-MAR-2009 was vaccinated with ZOSTAVAX (Merck) (lot # 663894/0129Y) SQ. On 05-MAR-2009 or 06-MAR-2009, 2 to 3 days after administration of ZOSTAVAX (Merck), the patient experienced injection site reactions. The patient experienced erythema, swelling, induration, pruritus, bruising and redness at the injection site. The pharmacist reported that most patients reported redness and itchiness immediately after administration. The patient had sought unspecified medical attention via telephone. At the time of reporting the patient's adverse events persisted. This is one of several reports from the same source. Additional information has been requested.
Age: 74.0
Sex: M
Vaccine: VARZOS
Symptoms: Injection site swelling
Clinical narrative: Information has been received from a pharmacist concerning a 74 year old male patient who on 03-MAR-2009 was vaccinated with ZOSTAVAX (Merck) (lot # 663894/0129Y) SQ. On 05-MAR-2009 or 06-MAR-2009, 2 to 3 days after administration of ZOSTAVAX (Merck), the patient experienced injection site reactions. The patient experienced erythema, swelling, induration, pruritus, bruising and redness at the injection site. The pharmacist reported that most patients reported redness and itchiness immediately after administration. The patient had sought unspecified medical attention via telephone. At the time of reporting the patient's adverse events persisted. This is one of several reports from the same source. Additional information has been requested.
Age: 84.0
Sex: M
Vaccine: VARZOS
Symptoms: Cough, Nasopharyngitis, Rhinorrhoea
Clinical narrative: Information has been received from a consumer concerning her husband, a 75 year old male patient, with no known drug reaction/allergies and with a history of Parkinson's disease, who was vaccinated with ZOSTAVAX (Merck) 2 weeks ago. Concomitant therapy included Carbidopa/Levodopa, Simvastatin (manufacturer unknown), Aspirin and Terazosin. The consumer reported that "1 week ago". The patient developed cold symptoms, runny nose and cough. At the time of the report, the patient was recovering. The patient did not seek medical attention. Additional information has been requested.
Age: 78.0
Sex: F
Vaccine: VARZOS
Symptoms: Dry skin, Incorrect route of drug administration, Skin discolouration, Skin induration
Clinical narrative: Information has been received from a 78 year old female consumer with PENICILLIN allergy who in approximately January 2009, was vaccinated with 0.65 ml of a dose of ZOSTAVAX (Merck) intramuscularly. Concomitant medications include heart medication, diabetes medication and for "everything" (unspecified medications). Within a week of the vaccination, the consumer reported that the skin "in my groin area" and on her chest "white, hard and rough". The consumer sought unspecified medical attention. The consumer did not want a follow up with her doctor. No further information is available.
Age: 65.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site rash, Rash vesicular
Clinical narrative: Information has been received from a physician concerning a 65 year old female patient who on unspecified date was vaccinated with a dose of ZOSTAVAX (Merck). On an unknown date, the patient developed zoster type rash at injection site after getting ZOSTAVAX (Merck). The patient sought unspecified medical attention. At the time of reporting, the patient had recovered. No further information is available.
Sex: U
Vaccine: VARZOS
Symptoms: Rash
Clinical narrative: Information has been received from a pharmacy student who heard second hand that a patient was vaccinated with a dose of ZOSTAVAX (Merck). Concomitant therapy included lisinopril, ADVAIR, metformin and aspirin. Three days later the patient developed a rash on the palms of hands and sole of feet. The outcome of the patient's rash on the palms of hands and soles of feet was not reported. All attempts to contact the pharmacy student were unsuccessful. No further information is available.
Sex: F
Vaccine: VARZOS
Symptoms: Rash vesicular
Clinical narrative: Information has been received from a registered pharmacist concerning an "over 65 year" old female patient who on 04-MAR-2009 was vaccinated with ZOSTAVAX (Merck) SQ. On 06-MAR-2009 the patient developed a shingles like rash. The patient "was convinced that she had gotten the shingles like rash from the vaccine". The patient had sought unspecified medical attention. The patient's shingles like rash improved after stopping therapy. Additional information has been requested.
Age: 67.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site pustule, Injection site scab
Clinical narrative: Information has been received from a registered nurse concerning a 67 year old female patient who "3 months ago" in approximately December 2008, was vaccinated with ZOSTAVAX (Merck). "1 week after vaccination", the patient had a scab that "look like a dried pustule" at the injection site. The patient was given ZOSTAVAX (Merck) by her physician and it was unknown if the physician was contacted. The patient's a scab that "look like a dried pustule" at the injection site persisted. Additional information has been requested.
Age: 70.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a Nurse Practitioner (N.P.) concerning a 71 year old female with hypertension and no drug allergies who on 05-FEB-2008 was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (lot# 658210/1079U). There was no concomitant medication. On 10-MAR-2009 the patient developed shingles. The shingles developed on her "left thorax". At the time of reporting (11-MAR-2009) the patient was not recovered. Follow up information was received from a Nurse Practitioner (N.P.) concerning the 70 year old female who on 05-FEB-2008 was vaccinated in the left arm with the first dose of ZOSTAVAX (Merck) (lot# 658210/1079U). The patient developed shingles 14 months after receiving the vaccine. On an unspecified date the patient was recovered. The patient sought medical attention and was seen by Nurse Practitioner. No further information is available.